PURE Bioscience  

(Public, OTCMKTS:PURE)   Watch this stock  
Find more results for NASDAQ:PURE
0.000 (0.00%)
Nov 26 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.75 - 0.77
52 week 0.47 - 1.57
Open 0.75
Vol / Avg. 12,525.00/72,865.00
Mkt cap 29.84M
P/E     -
Div/yield     -
EPS -0.45
Shares 39.78M
Beta 0.89
Inst. own 2%
Oct 28, 2014
Full Year 2014 PURE Biosciences Inc Earnings Call
Oct 28, 2014
Full Year 2014 PURE Biosciences Inc Earnings Release
Sep 10, 2014
Pure Biosciences Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Jul '14) 2014
Net profit margin -2011.28% -2009.09%
Operating margin -2003.76% -2031.82%
EBITD margin - -1618.18%
Return on average assets -497.88% -563.63%
Return on average equity -1635.58% -
Employees 12 -
CDP Score - -


EL CAJON, CA 92020
United States - Map
+1-619-5968600 (Phone)
+1-619-5968690 (Fax)

Website links


Pure Bioscience, Inc. (PURE) is focused on the discovery, development and commercialization of bioscience products. PURE�s technology platform is based on stabilized ionic silver, and its initial products contain silver dihydrogen citrate (SDC).The Company manufactures and sells SDC-based disinfecting and sanitizing products. PURE also manufactures and sells various SDC-based formulations to manufacturers for use as a raw material in the production of personal care and other products. The Company�s products include PURE Complete System, which includes PURE Hard Surface, PURE Multi-Purpose Cleaner Concentrate and PURE Floor Cleaner Concentrate; Axen 30; Axenohl, and Silverion.

Officers and directors

David Pfanzelter Independent Chairman of the Board
Age: 59
Henry R. Lambert Chief Executive Officer, Director
Age: 62
Peter C. Wulff Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Age: 54
Gary D. Cohee Director
Age: 67
Tom Y Lee CPA Director
William Otis Independent Director
Age: 57
David M. Theno Jr. Ph.D. Independent Director
Age: 62